Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

MW Weiner, DP Veitch, PS Aisen, LA Beckett… - Alzheimer's & …, 2017 - Elsevier
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued
development and standardization of methodologies for biomarkers and has provided an …

Alzheimer's disease and type 2 diabetes mellitus: A systematic review of proteomic studies

J Diniz Pereira, V Gomes Fraga… - Journal of …, 2021 - Wiley Online Library
Similar to dementia, the risk for developing type 2 diabetes mellitus (T2DM) increases with
age, and T2DM also increases the risk for dementia, particularly Alzheimer's disease (AD) …

[HTML][HTML] Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases

S Mayo, J Benito-León, C Peña-Bautista… - Current …, 2021 - ncbi.nlm.nih.gov
Background: Alzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly
folded modified proteins. Protein expression mechanisms are involved since the early …

A systematic review of longitudinal studies which measure Alzheimer's disease biomarkers

E Lawrence, C Vegvari, A Ower… - Journal of …, 2017 - content.iospress.com
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease, with no
effective treatment or cure. A gold standard therapy would be treatment to slow or halt …

Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection

C Peña-Bautista, C Vigor, JM Galano, C Oger… - Free Radical Biology …, 2018 - Elsevier
Abstract Introduction Alzheimer Disease (AD) standard diagnosis is based on evaluations
and biomarkers that are non-specific, expensive, or requires invasive sampling. Therefore …

Radiogenomics for precision medicine with a big data analytics perspective

AS Panayides, MS Pattichis, S Leandrou… - IEEE journal of …, 2018 - ieeexplore.ieee.org
Precision medicine promises better healthcare delivery by improving clinical practice. Using
evidence-based substratification of patients, the objective is to achieve better prognosis …

Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: A systematic review and meta-analysis

SH Rehiman, SM Lim, CF Neoh, ABA Majeed… - Ageing research …, 2020 - Elsevier
In order to gauge the impact of proteomics in discovery of Alzheimer's disease (AD) blood-
based biomarkers, this study had systematically reviewed articles published between 1984 …

Why inclusion matters for Alzheimer's disease biomarker discovery in plasma

MJ Khan, H Desaire, OL Lopez… - Journal of …, 2021 - content.iospress.com
Background: African American/Black adults have a disproportionate incidence of
Alzheimer's disease (AD) and are underrepresented in biomarker discovery efforts …

Predicting the prognosis of MCI patients using longitudinal MRI data

F Er, D Goularas - IEEE/ACM Transactions on Computational …, 2020 - ieeexplore.ieee.org
The aim of this study is to develop a computer-aided diagnosis system with a deep-learning
approach for distinguishing “Mild Cognitive Impairment (MCI) due to Alzheimer's Disease …

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease

J Muenchhoff, A Poljak, A Thalamuthu, VB Gupta… - Scientific reports, 2016 - nature.com
The autosomal dominant form of Alzheimer's disease (ADAD) is far less prevalent than late
onset Alzheimer's disease (LOAD), but enables well-informed prospective studies, since …